Objectives. The study was done to describe clinical and subclinical features and results of treatment of neonatal unconjugated hyperbilirubinemia due to maternal child blood group incompatibility at Haiphong Children’s Hospital from 2017 to 2022. Subjects and Methods. Subjects included 51 infants with UHBJ due to maternal-child blood group incompatibility. The method was a case-series report. Results and Conclusions. The male/female ratio was approximately 1:1. The majority of patients were normal newborns. A history of having a sibling with neonatal jaundice accounted for a low rate. Most of the cases with jaundice occurred 24 hours after birth, the cases occurring 72 hours after birth accounted for a low rate. Jaundice in zones 3 and 5 accounted for the highest rate. ABO incompatibility accounted for 78.4%, and Rh was 22.6%. Which OA form accounted for 45.1%, and the OB form was 33.3%. The average concentration of UB on admission was about 23.27± 5.72 mg%. After 24 h of PT, the average UB reduced by 5.82± 1.3 mg%. At the end of PT, the average UB was very low: 8.12± 3.89 mg% (The average UB reduced by 60% compared to that before the PT). Exchange transfusion reduced 50% UB right after ET (from 28.12± 4.83 mg% to 13.02± 5.9 mg%). After 48 h of ET, the average UB reduced to 10.6± 4.28 mg%, and after 72 h, it decreased to a very low level 9.1± 3.21 mg%. 84.3% of patients recovered, 5.9% were referred to higher hospitals. The average hospitalization time was 6.47± 2.76 (days).